EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer

Jiang Zhu, Shenao Fu, Xi Zou, Hanjiang Zeng, Guangzu Cui, Yinghui Peng, Diya Tang, Fan Zhang, Hong Shen, Shan Zeng, Ying Han iD

Advanced Science · 2025-07 · 12 (27)

DOI: 10.1002/advs.202500271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 08.05.2025. Verfasst von Jiang Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Xiangya Hospital, 87 Xiangya Road, Kaifu District, Central South University, Changsha, Hunan, 410008, P. R. China. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Colorectal Neoplasms, DNA Mismatch Repair. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Postdoctoral Science Foundation, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Microsatellite stable (MSS) colorectal cancer (CRC) is considered an “immune‐cold” tumor, accounting for ≈85% of all CRC cases. The overall response rate to chemotherapy combined with immune checkpoint inhibitors in MSS CRC is typically less than 10%. The specific mechanism that enhances chemotherapy sensitivity and mediated immunogenicity renders MSS CRC more responsive to immunotherapy remains elusive. Experiments in this study identify a DNA damage repair‐related epigenetic gene, protein arginine methyltransferase 5 (PRMT5), whose inhibition enhances Irinotecan (CPT‐11) sensitivity and synergistically induces a postmeiotic segregation increased 2 (PMS2)‐deficient‐like state, leading to the release of cytosolic double‐stranded DNA. This activates the cyclic GMP‐AMP synthase (cGAS)‐stimulator of the IFN gene (STING) signaling pathway, thereby enhancing anti‐tumor immunotherapy through dendritic cell‐T cell‐dependent functions. Importantly, combining the epigenetic anti‐tumor drug GSK3326595 with CPT‐11 significantly upregulates the immune receptor tyrosine‐based inhibitory motif (TIGIT) level on CD8+ T cells and subsequently demonstrates impressive anti‐tumor efficacy in vivo when additional anti‐TIGIT is included. Collectively, this study reveals the crucial role of PRMT5 blockade combined with CPT‐11 in inducing a mismatch repair deficiency‐like state and provides a novel triple‐drug combination therapy strategy as a potential treatment for patients with MSS CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesColorectal NeoplasmsDNA Mismatch RepairHumansAnimalsIrinotecanMiceDrug SynergismCell Line, TumorMicrosatellite InstabilityImmunotherapyFemale

Stichwörter der Autor:innen

PRMT5anti‐tumor immunitycGAS–STING signalingcolorectal cancerepigenetic therapies

Substanzen

Protein-Arginine N-MethyltransferasesIrinotecanPRMT5 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Xiangya Hospital, 87 Xiangya Road, Kaifu District, Central South University, Changsha, Hunan, 410008, P. R. China.
  • National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 87 Xiangya Road, Kaifu District, Central South University, Changsha, Hunan, 410008, P. R. China.
  • Department of Nephrology, Xingsha Campus, Hunan Provincial People's Hospital, Changsha, Hunan, 410100, P. R. China.
  • College of Life Science, Mudanjiang Medical University, Mudanjiang, 157011, P. R. China.
  • Key Laboratory for Molecular Radiation Oncology of Hunan Province, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, P. R. China.

ORCID-Profile: Ying Han

Förderung

  • National Natural Science Foundation of China
  • China Postdoctoral Science Foundation
  • Natural Science Foundation of Hunan Province
  • Nature Science Foundation of Changsha
  • CSCO Cancer Research Foundation

Zitieren

APA

Zhu, J., Fu, S., Zou, X., Zeng, H., Cui, G., Peng, Y., Tang, D., Zhang, F., Shen, H., Zeng, S., & Han, Y. (2025). PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer. Advanced Science, 12(27). https://doi.org/10.1002/advs.202500271

Vancouver

Zhu J, Fu S, Zou X, Zeng H, Cui G, Peng Y, et al. PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer. Advanced Science. 2025;12(27). doi:10.1002/advs.202500271

BibTeX
@article{Zhu2025,
  author = {Zhu, Jiang and Fu, Shenao and Zou, Xi and Zeng, Hanjiang and Cui, Guangzu and Peng, Yinghui and Tang, Diya and Zhang, Fan and Shen, Hong and Zeng, Shan and Han, Ying},
  title = {PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti‐TIGIT Therapy in Microsatellite‐Stable Colorectal Cancer},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {27},
  doi = {10.1002/advs.202500271}
}
Kostenlos starten →